Blood
Articles in this Issue
Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor
Abstract Introduction Some patients (pts) with chronic myeloid leukemia (CML) eventually develop disease resistance or treatment intolerance...
Two-decade trends and future projections of heart failure mortality in Myelodysplastic Syndromes: A nationwide population-based study (1999–2030)
Abstract Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that predominantly affect older adults and are chara...
B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy
Abstract Introduction: Using cell-free RNA (cfRNA) in liquid biopsy (LBx) is emerging as an added approach for refining and expanding the ut...
Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement
Abstract Background Central nervous system involvement in multiple myeloma (CNS-MM) is a rare but highly aggressive mani...
BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study
Abstract Introduction: Patients with relapsed or refractory (R/R) AML or high-risk MDS (HR-MDS) have limited therapeutic...
Plasma cell senescence in relapsed multiple myeloma revealed by integrated single-cell RNA-seq analysis
Abstract Introduction: Multiple myeloma (MM) is an incurable plasma cell (PC) malignancy, in which nearly all patients are expected to relap...
A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia
Abstract Introduction: The molecular heterogeneity of acute myeloid leukemia (AML) complicates clinical assessments for optimal therapeutic...
Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study
Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, with relapse rates of 30–40%...
Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).
Abstract Introduction: Patients with coexisting MYD88L265P and CD79B mutations (MCD subtype) of diffuse large B-cell lymphoma (DLBCL) exhibi...
Tumor-associated macrophages (CD68+) as a potential prognostic biomarker for PD-1 inhibitor response in relapsed/refractory classical Hodgkin lymphoma
Abstract Objective: Despite the significant clinical efficacy of PD-1 blockade in relapsed or refractory classical Hodgkin lymphoma (R/R cHL...
Machine learning-based body composition analysis for risk stratification in newly diagnosed diffuse large B cell lymphoma
Abstract Frailty is an adverse prognostic factor in cancer, including diffuse large B-cell lymphoma (DLBCL). Although frailty is common amon...
Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP
Abstract INTRODUCTION Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma (HL)...
Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML
Abstract Background: Intensive chemotherapy (IC) regimen is the standard of care and the only curative treatment for acute myeloid leukemia...
Sustained measurable residual disease (MRD) in light chain amyloidosis: The added value of durability over depth alone
Abstract Introduction In light chain (AL) amyloidosis, patients achieving hematologic complete response (hemCR) may still harbor residual cl...
Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor
Abstract Background: Pediatric patients with chronic myeloid leukemia (CML) who present in blast phase (de novo BP) make up about 7-10% of c...
Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions
Abstract Background: In recent decades, standard upfront therapy for mantle cell lymphoma (MCL) has featured chemoimmunotherapy (CIT) regime...
DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre
Abstract Background Germline DDX41 mutations are the most common genetic predisposition to myeloid neoplasms, representing a distinct subtyp...
An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation
Abstract Introduction: Haploidentical peripheral blood allogeneic hematopoietic cell transplantation (PB haplo-HCT) can be complicated by gr...
Real-world incidence of HLH-like syndromes across CAR T-cell products: A multi-institutional cohort study using the trinetx network
Abstract Background: Hemophagocytic lymphohistiocytosis (HLH)–like syndromes are rare but potentially life-threatening c...
The Acute Myeloid Leukemia microenvironment is defined by ineffective immune surveillance despite the presence of activated, clonally-expanded CD8 T cells with preserved effector function
Abstract T cell-based immunotherapies have shown limited efficacy in acute myeloid leukemia (AML), likely due to an incomplete understanding...
Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel
Abstract Introduction. Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 has transformed the treatment landscape for patients...
Fostamatinib significantly increases risk of hypertension in hematologic patients: A meta-analysis of randomized trials
Abstract Introduction: Fostamatinib, an oral spleen tyrosine kinase inhibitor, is approved for the treatment of chronic immune thrombocytope...
Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia
Abstract While venetoclax (VEN) combined with hypomethylating agents (HMA) has greatly advanced outcomes for acute myeloid leukemia (AML), r...
Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis
Abstract INTRODUCTION The introduction of tyrosine kinase inhibitors (TKIs) has significantly increased the survival of patients (pts) with c...
Baseline [18F] FDG PET biomarkers of host and tumor predict efficacy and CRS in multiple myeloma patients treated with CAR-T cell therapy
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for Relapsed/Refractory multipl...